Mathematical Models of the Impact of IL2 Modulation Therapies on T Cell Dynamics

Several reports in the literature have drawn a complex picture of the effect of treatments aiming to modulate IL2 activity in vivo. They seem to promote either immunity or tolerance, probably depending on the specific context, dose, and timing of their application. Such complexity might derive from the pleiotropic role of IL2 in T cell dynamics. To theoretically address the latter possibility, our group has developed several mathematical models for Helper, Regulatory, and Memory T cell population dynamics, which account for most well-known facts concerning their relationship with IL2. We have simulated the effect of several types of therapies, including the injection of: IL2; antibodies anti-IL2; IL2/anti-IL2 immune-complexes; and mutant variants of IL2. We studied the qualitative and quantitative conditions of dose and timing for these treatments which allow them to potentiate either immunity or tolerance. Our results provide reasonable explanations for the existent pre-clinical and clinical data, predict some novel treatments, and further provide interesting practical guidelines to optimize the future application of these types of treatments.

[1]  D. Lauffenburger,et al.  High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. , 2005, Biochemistry.

[2]  J. Sprent,et al.  IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor α subunit CD25 , 2010, Proceedings of the National Academy of Sciences.

[3]  J. Kahn,et al.  Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. , 2000, JAMA.

[4]  D. Klatzmann,et al.  Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. , 2010, The Journal of clinical investigation.

[5]  Vijay S. Pande,et al.  Exploiting a natural conformational switch to engineer an Interleukin-2 superkine , 2012, Nature.

[6]  S. Rosenberg,et al.  IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.

[7]  J. Shimizu,et al.  Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. , 2000, International immunology.

[8]  J. Sprent,et al.  Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes , 2006, Science.

[9]  A. Church Clinical advances in therapies targeting the interleukin-2 receptor. , 2003, QJM : monthly journal of the Association of Physicians.

[10]  J. Carneiro,et al.  Modelling T-cell-mediated suppression dependent on interactions in multicellular conjugates. , 2000, Journal of theoretical biology.

[11]  A. Freitas,et al.  Homeostasis of Peripheral CD4+ T Cells: IL-2Rα and IL-2 Shape a Population of Regulatory Cells That Controls CD4+ T Cell Numbers1 , 2002, The Journal of Immunology.

[12]  S. Zheng,et al.  IL-2 Is Essential for TGF-β to Convert Naive CD4+CD25− Cells to CD25+Foxp3+ Regulatory T Cells and for Expansion of These Cells1 , 2007, The Journal of Immunology.

[13]  K. Leon,et al.  Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: a versatile platform for fine epitope mapping. , 2013, Immunobiology.

[14]  K. Leon,et al.  Modeling the role of IL2 in the interplay between CD4+ helper and regulatory T cells: studying the impact of IL2 modulation therapies. , 2012, International immunology.

[15]  A. Tyznik,et al.  Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells , 2006, Nature.

[16]  Shimon Sakaguchi,et al.  Homeostatic maintenance of natural Foxp3 + CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization , 2005, The Journal of experimental medicine.

[17]  E. Wherry,et al.  Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo , 2003, Nature Medicine.

[18]  T. Malek,et al.  Normal Lymphoid Homeostasis and Lack of Lethal Autoimmunity in Mice Containing Mature T Cells with Severely Impaired IL-2 Receptors1 , 2000, The Journal of Immunology.

[19]  Ethan M. Shevach,et al.  CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.

[20]  A recombinant turkey herpesvirus expressing chicken interleukin-2 increases the protection provided by in ovo vaccination with infectious bursal disease and infectious bronchitis virus. , 2007, Vaccine.

[21]  C. Hallahan,et al.  Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. , 2002, Blood.

[22]  G. Pantaleo,et al.  IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. , 2009, The Journal of allergy and clinical immunology.

[23]  Kendall A. Smith,et al.  Interleukin-2: inception, impact, and implications. , 1988, Science.

[24]  K. Leon,et al.  Modeling the role of IL-2 in the interplay between CD4+ helper and regulatory T cells: assessing general dynamical properties. , 2010, Journal of theoretical biology.

[25]  J. Pow-Sang,et al.  Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma , 2008, Journal of immunotherapy.

[26]  J. Metcalf,et al.  In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. , 2005, The Journal of clinical investigation.

[27]  T. Hünig,et al.  Control of T cell hyperactivation in IL‐2‐deficient mice by CD4+CD25– and CD4+CD25+ T cells: evidence for two distinct regulatory mechanisms , 2001, European journal of immunology.

[28]  Ana R. Pacios,et al.  Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2 , 2013, The Journal of Immunology.

[29]  E. Montero,et al.  Interleukin‐2 Mastering Regulation in Cancer and Autoimmunity , 2007, Annals of the New York Academy of Sciences.

[30]  J. Sprent,et al.  Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease , 2006, Expert opinion on biological therapy.

[31]  J. Metcalf,et al.  Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. , 1996, The New England journal of medicine.

[32]  C. van den Dool,et al.  When three is not a crowd: a Crossregulation Model of the dynamics and repertoire selection of regulatory CD4+ T cells , 2007, Immunological reviews.

[33]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[34]  T. Hünig,et al.  evidence for two distinct regulatory mechanisms , 2001 .

[35]  R. Lempicki,et al.  Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Schlom,et al.  IL-2/Anti-IL-2 Antibody Complex Enhances Vaccine-Mediated Antigen-Specific CD8+ T Cell Responses and Increases the Ratio of Effector/Memory CD8+ T Cells to Regulatory T Cells1 , 2008, The Journal of Immunology.

[37]  M. Veldhoen,et al.  CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. , 2005, International immunology.

[38]  Antonio A. Freitas,et al.  Indexation as a Novel Mechanism of Lymphocyte Homeostasis: The Number of CD4+CD25+ Regulatory T Cells Is Indexed to the Number of IL-2-Producing Cells1 , 2006, The Journal of Immunology.

[39]  J. Bluestone,et al.  Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. , 2008, Immunity.

[40]  Y. Soong,et al.  DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. , 2007, Immunology letters.

[41]  J. Schlom,et al.  Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity , 2007, Cancer Immunology, Immunotherapy.

[42]  Kendall A. Smith,et al.  The structure of IL2 bound to the three chains of the IL2 receptor and how signaling occurs , 2006, Medical immunology.

[43]  T. Hirano,et al.  IL-2 In Vivo Activities and Antitumor Efficacy Enhanced by an Anti-IL-2 mAb1 , 2006, The Journal of Immunology.

[44]  T. Fujita,et al.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.

[45]  S. Kim-Schulze,et al.  Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Bluestone,et al.  IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells , 2010, The Journal of experimental medicine.

[47]  J. Metcalf,et al.  In vivo expansion of CD4+CD45RO–CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patients , 2005 .

[48]  S. Morrison,et al.  In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. , 1996, Journal of immunology.

[49]  M. Bevan,et al.  Naive CD8+ T cells differentiate into protective memory-like cells after IL-2–anti–IL-2 complex treatment in vivo , 2007, The Journal of experimental medicine.

[50]  G. Pantaleo,et al.  Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells , 2010, Proceedings of the National Academy of Sciences.

[51]  Kendall A. Smith,et al.  The quantal theory of how the immune system discriminates between "self and non-self" , 2004, Medical immunology.